WVE On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart

wave life sciences ltd (WVE) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WAVE LIFE SCIENCES LTD (WVE)
\

Related News

No related news articles were found.

wave life sciences ltd (WVE) Related Businessweek News

No Related Businessweek News Found

wave life sciences ltd (WVE) Details

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

250 Employees
Last Reported Date: 03/1/19
Founded in 2012

wave life sciences ltd (WVE) Top Compensated Officers

President, CEO & Director
Total Annual Compensation: $854.6K
Chief Financial Officer
Total Annual Compensation: $501.9K
Chief Medical Officer
Total Annual Compensation: $615.4K
Senior Vice President of Drug Discovery
Total Annual Compensation: $573.8K
Senior VP of Corporate Development & Head of ...
Total Annual Compensation: $493.1K
Compensation as of Fiscal Year 2018.
wave life sciences ltd
Wave Life Sciences Ltd. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 02:00 PM

Wave Life Sciences Ltd. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 02:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Paul B. Bolno, President, CEO & Director.

Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2019

Wave Life Sciences Ltd. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 3.026 million compared to USD 1.422 million a year ago. Operating loss was USD 47.988 million compared to USD 35.775 million a year ago. Net loss was USD 44.200 million compared to USD 35.241 million a year ago. Basic loss per share was USD 1.36 compared to USD 1.26 a year ago.

Wave Life Sciences Ltd. Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Wave Life Sciences Ltd. announced the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The company also announced the design of its planned Phase 2/3 clinical trial of suvodirsen in DMD, DYSTANCE 51. The Phase 1 data and DYSTANCE 51 details will be presented at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida. Wave’s Phase 1 clinical trial was a global, multicenter, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and plasma concentrations of single ascending doses of suvodirsen administered intravenously. Thirty-six patients received a dose of 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg, 7 mg/kg or 10 mg/kg of suvodirsen (n=26) or placebo (n=10) in five ascending dose cohorts and were followed for 85 days. No serious adverse events, deaths or discontinuations due to adverse events were reported in any study patients treated with suvodirsen. Based on results of the first four ascending dose cohorts, the independent Safety Monitoring Committee of the Phase 1 clinical trial endorsed continued dose exploration by proceeding to the last planned cohort. Doses of 7 mg/kg or 10 mg/kg of suvodirsen were administered to two patients in the fifth cohort and were associated with similar adverse events as those observed at lower doses but were more severe in intensity. The full data from the Phase 1 clinical trial will be presented in an oral presentation and poster at today’s MDA conference. In a second poster, Wave will present the design of DYSTANCE 51, a global, multicenter, randomized, double-blind, placebo-controlled Phase 2/3 efficacy and safety clinical trial of suvodirsen in DMD patients amenable to exon 51 skipping. This clinical trial is designed to enroll boys who are between 5 and 12 years of age (inclusive) with a genetically confirmed diagnosis of DMD amenable to exon 51 skipping therapy. Patients will be randomized to receive 4.5 mg/kg or 3 mg/kg of suvodirsen or placebo administered intravenously once weekly for 48 weeks. The 4.5 mg/kg dose in DYSTANCE 51 provides approximately the same amount of active ingredient as the 5 mg/kg dose in the Phase 1 clinical trial. Both doses have been selected based on the Phase 1 clinical trial results as well as data from in vitro and in vivo nonclinical studies. The DYSTANCE 51 primary efficacy endpoints will measure change in dystrophin protein level and change in the North Star Ambulatory Assessment score. In addition, this Phase 2/3 clinical trial will include multiple functional outcome measures as secondary efficacy endpoints. DYSTANCE 51 is expected to be initiated in July 2019 and the company intends to use the results of this trial to seek regulatory approvals globally. Earlier this year, Wave announced that the DYSTANCE 51 clinical trial was selected for the U.S. Food and Drug Administration (FDA) pilot program for complex innovative trial designs. As a participant in the pilot program, the company has additional opportunities to meet with FDA staff to discuss the design elements of the trial, including the potential use of Bayesian methods to adapt the trial with the aim of allowing for more efficient and productive clinical determinations.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

WVE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WVE.
View Industry Companies
 

Industry Analysis

WVE

Industry Average

Valuation WVE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.3x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact WAVE LIFE SCIENCES LTD, please visit www.wavelifesciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.